China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca

* FibroGen (NASDAQ:FGEN [https://seekingalpha.com/symbol/FGEN]) said on Monday that the China State Administration for Market Regulation has approved the sale [https://seekingalpha.com/pr/20203338-fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state] of FibroGen International to AstraZeneca Treasury Limited.
* The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025.
* FibroGen (NASDAQ:FGEN [https://seekingalpha.com/symbol/FGEN]) shares were up more than 3% in premarket trading.

MORE ON FIBROGEN

* FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812444-fibrogen-inc-fgen-q2-2025-earnings-call-transcript]
* FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances [https://seekingalpha.com/news/4483630-fibrogen-raises-china-sale-guidance-to-210m-extends-cash-runway-into-2028-as-phase-ii]
* FibroGen to implement 1-for-25 reverse stock split; shares down 15% [https://seekingalpha.com/news/4457761-fibrogen-to-implement-1-for-25-reverse-stock-split-shares-down-15]
* Seeking Alpha’s Quant Rating on FibroGen [https://seekingalpha.com/symbol/FGEN/ratings/quant-ratings]
* Historical earnings data for FibroGen [https://seekingalpha.com/symbol/FGEN/earnings]